Development and Qualification of a Drug-Disease Modeling Platform to Characterize Clinically Relevant Endpoints in Type 2 Diabetes Trials

scientific article published on 22 December 2017

Development and Qualification of a Drug-Disease Modeling Platform to Characterize Clinically Relevant Endpoints in Type 2 Diabetes Trials is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1002/CPT.998
P698PubMed publication ID29271001

P2093author name stringJenny Y Chien
Stephan Schmidt
Puneet Gaitonde
Parag Garhyan
Felipe K Hurtado
P2860cites workDeteriorating beta-cell function in type 2 diabetes: a long-term modelQ44372257
Mathematical models of diabetes progressionQ44864538
A mechanism-based disease progression model for comparison of long-term effects of pioglitazone, metformin and gliclazide on disease processes underlying Type 2 Diabetes Mellitus.Q51501369
Beta-cell deterioration determines the onset and rate of progression of secondary dietary failure in type 2 diabetes mellitus: the 10-year follow-up of the Belfast Diet Study.Q51570046
Xpose--an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEMQ77296898
Disease system analysis: basic disease progression models in degenerative diseaseQ80390429
Homeostasis model assessment: insulin resistance and ?-cell function from fasting plasma glucose and insulin concentrations in manQ26776977
Use and abuse of HOMA modelingQ28263292
Analysis of combination drug therapy to develop regimens with shortened duration of treatment for tuberculosisQ28540482
Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects modelsQ30499990
Application of a mechanism-based disease systems model for osteoporosis to clinical dataQ34546981
Beta-cell dysfunction and insulin resistance in type 2 diabetes: role of metabolic and genetic abnormalitiesQ34996991
The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of Type 2 diabetesQ35085591
Evaluation of the long-term durability and glycemic control of fasting plasma glucose and glycosylated hemoglobin for pioglitazone in Japanese patients with type 2 diabetes.Q35138216
Coping with time scales in disease systems analysis: application to bone remodelingQ35591581
Pathogenesis of type 2 diabetes mellitusQ35861736
Diagnosing model diagnosticsQ36850144
Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitusQ37141727
Systems approaches in risk assessment.Q38093360
Future glucose-lowering drugs for type 2 diabetes.Q38711383
Modeling and Simulation Workbench for NONMEM: Tutorial on Pirana, PsN, and XposeQ41454681
A model for glucose, insulin, and beta-cell dynamics in subjects with insulin resistance and patients with type 2 diabetesQ43059458
P407language of work or nameEnglishQ1860
P577publication date2017-12-22
P1433published inClinical Pharmacology & TherapeuticsQ1101529
P1476titleDevelopment and Qualification of a Drug-Disease Modeling Platform to Characterize Clinically Relevant Endpoints in Type 2 Diabetes Trials

Search more.